Developing new treatments for burn wound infections caused by antibiotic-resistant bacteria.
Proof of concept experiments for T3SS inhibitors against burn wound infections
This study is looking at a new treatment to help fight infections from a tough bacteria called Pseudomonas aeruginosa that can affect burn wounds, and if successful, it could offer better care for patients dealing with these kinds of infections.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Microbiotix, INC NIH-funded |
| Lab location | 1 site (Worcester, United States) |
| Project ID | NIH-11074661 on NIH RePORTER |
What this research studies
This research focuses on creating a new therapy to combat burn wound infections caused by the bacteria Pseudomonas aeruginosa, which is known for its resistance to many antibiotics. The approach involves testing small molecules that inhibit a specific system used by the bacteria to infect and spread within the body. By targeting the type 3 secretion system (T3SS), the research aims to reduce the bacteria's ability to cause harm. Patients with burn wounds may benefit from this innovative treatment if it proves effective.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with burn wounds who are at risk of infection from Pseudomonas aeruginosa.
Not a fit: Patients with burn wounds not infected by Pseudomonas aeruginosa or those with other types of infections may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients suffering from burn wound infections, particularly those caused by antibiotic-resistant bacteria.
How similar studies have performed: Previous research has shown promise in targeting the T3SS in similar bacterial infections, indicating potential for success in this novel approach.
Where this research is happening
Worcester, United States
- Microbiotix, INC — Worcester, United States (Active)
Researchers
- Principal investigator: Opperman, Timothy J. — Microbiotix, INC
- Study coordinator: Opperman, Timothy J.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.